Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEC2Olkh|ryP M{LodnNCVkeHUh?=
MV-4-11 M37Ye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFziZXNKSzVyPUCuNFE2QDZizszN NXnDRZNsW0GQR1XS
NKM-1 M3riZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\hfIExUUN3ME2wMlAyPjl7IN88US=> NFPNWWRUSU6JRWK=
ML-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\yV3RUUUN3ME2wMlAyQTh|IN88US=> NVTnSI9mW0GQR1XS
BV-173 NGKwOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEKzNVQh|ryP Mn7kV2FPT0WU
RS4-11 M1HIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3QXXp4UUN3ME2wMlAzPTh5IN88US=> MWLTRW5ITVJ?
HL-60 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXyTWM2OD1yLkCyPVA5KM7:TR?= M3\Mc3NCVkeHUh?=
KY821 M1zU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzQdoZKSzVyPUCuNFI6PzVizszN M2DUOXNCVkeHUh?=
ECC10 NELwPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\CdmlEPTB;MD6wN|c6OiEQvF2= NWLROlBFW0GQR1XS
NCI-H720 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPqeXluUUN3ME2wMlA1ODFzIN88US=> MV7TRW5ITVJ?
QIMR-WIL NF;mdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKyfJB3UUN3ME2wMlA1Ojh5IN88US=> NYDSOW9{W0GQR1XS
KG-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMES0PFYh|ryP NEi2NlVUSU6JRWK=
TGW MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDTTWM2OD1yLkC0OlM{KM7:TR?= Ml3EV2FPT0WU
ATN-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMES3N|Mh|ryP MY\TRW5ITVJ?
RH-18 M1XRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu0TWM2OD1yLkC2NFQ5KM7:TR?= MWDTRW5ITVJ?
EW-18 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrBXYhwUUN3ME2wMlA3QDRzIN88US=> MUHTRW5ITVJ?
NB17 NF3ZTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEexNlQh|ryP NV3PPG91W0GQR1XS
SK-NEP-1 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjqRXJHUUN3ME2wMlA4OjF|IN88US=> MWLTRW5ITVJ?
P12-ICHIKAWA NV\0c2dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm4TWM2OD1yLkC3O|c5KM7:TR?= MmDjV2FPT0WU
KARPAS-45 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzU[3JKSzVyPUCuNFc5OTVizszN M{K2[HNCVkeHUh?=
EW-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1yLkC4NFU{KM7:TR?= MnW1V2FPT0WU
NB13 M1O2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3RTWM2OD1yLkC4NlA{KM7:TR?= M3\EZ3NCVkeHUh?=
NCI-H209 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\xcJdKSzVyPUCuNFg4ODRizszN NXvyR|dwW0GQR1XS
NCI-H1092 NGjJRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\jSGlEPTB;MD6xNFI4PSEQvF2= M4XQOXNCVkeHUh?=
NH-12 NX3TPFhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMUC3OFQh|ryP MnzxV2FPT0WU
697 NF3wc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Dq[WlEPTB;MD6xNFg{QSEQvF2= M1X0VnNCVkeHUh?=
KE-37 NGeyWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMUGzO{DPxE1? MUPTRW5ITVJ?
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMUWxOlkh|ryP M3n1bHNCVkeHUh?=
CHP-134 M2faNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMU[zNFYh|ryP NFzydVFUSU6JRWK=
D-283MED NXjD[lF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ntZWlEPTB;MD6xO|Y5PiEQvF2= MnXnV2FPT0WU
LU-135 NH;6V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\VOlhKSzVyPUCuNVg2PTJizszN MlG2V2FPT0WU
LU-134-A NVHyT3hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37URWlEPTB;MD6xPFY4OSEQvF2= MmnuV2FPT0WU
EM-2 NHfIWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHCdWRlUUN3ME2wMlE6QTF6IN88US=> MYTTRW5ITVJ?
LU-139 M3K2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6NotKSzVyPUCuNlA1QThizszN NXzrVIlyW0GQR1XS
ALL-PO NHHWXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMkG5PFgh|ryP MWXTRW5ITVJ?
NB12 NHjYZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknMTWM2OD1yLkKzNVE2KM7:TR?= NH;mUopUSU6JRWK=
KP-N-YN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDMTWM2OD1yLkKzOVc{KM7:TR?= NFXtcVhUSU6JRWK=
BEN NFTjUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMkO5Olgh|ryP NV3lSpduW0GQR1XS
HCC1569 NIPQT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jwdGlEPTB;MD6yOVExPiEQvF2= NIPmSWhUSU6JRWK=
HuO9 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DxU2lEPTB;MD6yOlcyPSEQvF2= MV\TRW5ITVJ?
WM-115 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULkSXpnUUN3ME2wMlI4PzN6IN88US=> MX7TRW5ITVJ?
CCRF-CEM NInFOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvxTWM2OD1yLkOzOVI6KM7:TR?= NGO5fFBUSU6JRWK=
IST-SL1 NUHNXZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rYfmlEPTB;MD6zOVM1OyEQvF2= NXjkWI1QW0GQR1XS
BE-13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwM{[0OVkh|ryP M3LvXXNCVkeHUh?=
COR-L88 NXjrPW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInGfmFKSzVyPUCuN|Y2PCEQvF2= NVu0cWFvW0GQR1XS
DOHH-2 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[zVXE{UUN3ME2wMlQyODJ|IN88US=> MlryV2FPT0WU
A704 NFvqUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T0TWlEPTB;MD60NlY4KM7:TR?= NVrab492W0GQR1XS
KNS-81-FD MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPkVFA4UUN3ME2wMlQ1ODF5IN88US=> MUPTRW5ITVJ?
RPMI-8226 NFzKcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPvU2c{UUN3ME2wMlQ2PjV{IN88US=> MlPEV2FPT0WU
TGBC24TKB M1ixWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr2VZVPUUN3ME2wMlQ2Pzd6IN88US=> MV;TRW5ITVJ?
NCI-H1304 NHe0SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nuVWlEPTB;MD60OlE2PyEQvF2= NX3GTphDW0GQR1XS
MOLT-13 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TqVGlEPTB;MD60OlYyOyEQvF2= NWnMcmRRW0GQR1XS
EW-22 M4[xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPETWM2OD1yLkS2OlcyKM7:TR?= MXvTRW5ITVJ?
MS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Hr[mlEPTB;MD60Olk{OyEQvF2= M2G0NnNCVkeHUh?=
RMG-I MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm0RXlmUUN3ME2wMlQ6PDZ2IN88US=> MmCyV2FPT0WU
NTERA-S-cl-D1 NYPKPXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjLTWM2OD1yLkWwNFE6KM7:TR?= MUTTRW5ITVJ?
NCI-H1048 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHruZotKSzVyPUCuOVA6PTNizszN M3TxTnNCVkeHUh?=
SW1417 M{HoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLldYFUUUN3ME2wMlU2PDN6IN88US=> NY\HV3NIW0GQR1XS
DB NXTJdFFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zmWmlEPTB;MD61O|A5KM7:TR?= NGPnToFUSU6JRWK=
MEG-01 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DmcmlEPTB;MD61PFMzKM7:TR?= NFO2RZpUSU6JRWK=
EW-13 NGrwc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\ncVZKSzVyPUCuOVg{PDFizszN MoixV2FPT0WU
LAMA-84 NF\FXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwNUmyNFch|ryP Mnz0V2FPT0WU
J-RT3-T3-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK5TnRzUUN3ME2wMlYxQDB6IN88US=> MkDUV2FPT0WU
MOLT-16 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNkWyOlQh|ryP MkX4V2FPT0WU
DU-4475 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljyTWM2OD1yLk[1OFI4KM7:TR?= M1HVfXNCVkeHUh?=
HAL-01 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvBTWM2OD1yLkeyOVQ6KM7:TR?= NHnPXVVUSU6JRWK=
RD NV\YUpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwN{W4PVkh|ryP MlfmV2FPT0WU
OAW-28 NXTvXW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rXU2lEPTB;MD63PFM4KM7:TR?= MXfTRW5ITVJ?
HCC38 NXnh[YZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHCTWJiUUN3ME2wMlgxOTlizszN MljRV2FPT0WU
NMC-G1 NInze5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7sWIFnUUN3ME2wMlgyOTJzIN88US=> NVXhd|V1W0GQR1XS
EW-16 M1z3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LZUmlEPTB;MD64NVMzQCEQvF2= M2Twb3NCVkeHUh?=
DU-145 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\EfGlEPTB;MD64PVkzOyEQvF2= M4DJN3NCVkeHUh?=
HPAF-II NFLtT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwOUK2Nlgh|ryP M3rLW3NCVkeHUh?=
A427 M1q5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHiTWM2OD1yLkmzNFIzKM7:TR?= M1PCbHNCVkeHUh?=
PA-1 NXfmcIFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlroTWM2OD1yLkm1OlQzKM7:TR?= NYHIdId1W0GQR1XS
OAW-42 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDPRoZKSzVyPUCuPVYyPDZizszN NWLWXZhoW0GQR1XS
L-428 NU\IZ3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjNcldKSzVyPUGuNFEzPSEQvF2= MWTTRW5ITVJ?
COLO-824 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwMEG3NFgh|ryP NHny[2NUSU6JRWK=
P30-OHK MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwMES2PFgh|ryP Mn3aV2FPT0WU
NCI-H2170 M4PQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwME[yN{DPxE1? MUDTRW5ITVJ?
HCC2998 M17mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX1OnJWUUN3ME2xMlA4OTN3IN88US=> Mk\iV2FPT0WU
NB14 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHITWM2OD1zLkGzO|Q5KM7:TR?= NEHnb3lUSU6JRWK=
TGBC1TKB NFv4W4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTEU4tqUUN3ME2xMlE1OTV{IN88US=> M1T4OnNCVkeHUh?=
KP-N-YS NV\MWGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwMU[yN|Yh|ryP NGrydWZUSU6JRWK=
CAL-120 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3PZmNKSzVyPUGuNVY1OjlizszN NFTtTI1USU6JRWK=
SBC-1 M3nhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwMUmwOVMh|ryP NU\2TVUzW0GQR1XS
C32 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHtd5FKSzVyPUGuNVkxQDhizszN NFq1[XpUSU6JRWK=
HCC2157 M1jITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMUm0PVQh|ryP NF7DNJhUSU6JRWK=
COLO-792 NX\LUZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[3bGlEPTB;MT6yNFA4OSEQvF2= M3zCSnNCVkeHUh?=
ES7 MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jQTGlEPTB;MT6yO|k2OSEQvF2= NFW3R3pUSU6JRWK=
HEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lWmlEPTB;MT6zNVAzQSEQvF2= Mn\xV2FPT0WU
ES4 M1r0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33EO2lEPTB;MT6zOFk6QCEQvF2= NH7zS4FUSU6JRWK=
NCI-SNU-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDKTWM2OD1zLkO2OVU2KM7:TR?= NG\oUllUSU6JRWK=
MDA-MB-415 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrmUGtKSzVyPUGuN|g5PSEQvF2= NGTXN|FUSU6JRWK=
NCI-H2342 NX\ldoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5Z2lEPTB;MT60NFI3QSEQvF2= MUXTRW5ITVJ?
NB69 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNE[yO|Eh|ryP MmDWV2FPT0WU
D-247MG NVjJdW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwNUGxNlIh|ryP M2SzUnNCVkeHUh?=
SCC-4 NV\L[3VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLyTWM2OD1zLkW5PFg4KM7:TR?= NU\PfZFkW0GQR1XS
HuH-7 NHqwUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPqTWM2OD1zLk[3Nlk{KM7:TR?= MWXTRW5ITVJ?
A388 NW\NVlNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;QTWM2OD1zLk[4O|I1KM7:TR?= M1vvbXNCVkeHUh?=
Calu-3 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXVSHdKSzVyPUGuO|A3QTdizszN M1HKSXNCVkeHUh?=
NCI-H1648 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjkZnVKSzVyPUGuO|E1OThizszN MXrTRW5ITVJ?
NCI-H2052 NGPEeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLxco1qUUN3ME2xMlczOjBzIN88US=> NYjHR2NwW0GQR1XS
Ramos-2G6-4C10 M1L5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwN{O2OVYh|ryP M1[2enNCVkeHUh?=
DEL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOcGlEPTB;MT63OFY6OiEQvF2= M2e3dnNCVkeHUh?=
SNU-423 NVn0UXVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;6PWlEPTB;MT63PFE2PyEQvF2= NH7NXYdUSU6JRWK=
COR-L23 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLuT5BKSzVyPUGuO|k5PzRizszN MmTDV2FPT0WU
OMC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FTWM2OD1zLki2NFE3KM7:TR?= MkPIV2FPT0WU
EW-11 M1jvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwOUW2OVch|ryP MUTTRW5ITVJ?
HSC-3 NHLZWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPIWYx[UUN3ME2xMlk3OzZ3IN88US=> MmDrV2FPT0WU
MLMA NUX5SFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD1zLkm2Olc4KM7:TR?= M4C3TnNCVkeHUh?=
RCM-1 M3vvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XBVWlEPTB;Mj6wNFM6QSEQvF2= MmjqV2FPT0WU
MFE-280 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwMEK4OFgh|ryP MkXVV2FPT0WU
ES8 NHXud3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwMkW0O|Eh|ryP M4j5bnNCVkeHUh?=
TE-11 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwMkm0O|Mh|ryP MXnTRW5ITVJ?
HuO-3N1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HKfWlEPTB;Mj60PFc5KM7:TR?= NIi5eZlUSU6JRWK=
MHH-NB-11 M3TjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwNUGxOVgh|ryP MoTMV2FPT0WU
TGBC11TKB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fabWlEPTB;Mj61O|Y5OSEQvF2= NGfqTGlUSU6JRWK=
HOP-92 MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKyZ3dKSzVyPUKuOVg4PDNizszN MkKzV2FPT0WU
IGR-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwNkKwN|Uh|ryP MnXsV2FPT0WU
GOTO NIGyXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHHTWM2OD1{Lk[1N|c4KM7:TR?= MVLTRW5ITVJ?
NCI-H1650 M3q5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3QXVNKSzVyPUKuO|IzOTVizszN NE\LfVVUSU6JRWK=
NCI-H1581 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDJZXdKSzVyPUKuO|k3QDFizszN NUHJempOW0GQR1XS
NCI-H2405 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXVU|RKSzVyPUKuPFI4QDJizszN MnfVV2FPT0WU
U-118-MG MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK1TWM2OD1{Lkm2OFkyKM7:TR?= Mn7rV2FPT0WU
DoTc2-4510 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzfWx2UUN3ME2zMlAyPDF5IN88US=> MmfCV2FPT0WU
NCI-H596 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnETWM2OD1|LkC0PVk4KM7:TR?= NUn2W3BjW0GQR1XS
MPP-89 NVvMSGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInwVWNKSzVyPUOuNFU3PjZizszN NFryUlFUSU6JRWK=
GCIY MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhZ3ZKSzVyPUOuNlA1QTFizszN Mlq3V2FPT0WU
SW626 NU\IZmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPTc4tKSzVyPUOuNlQ2PDNizszN M1v0XHNCVkeHUh?=
OCI-AML2 M4jReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDtUlJKSzVyPUOuN|EzPzJizszN M13wXHNCVkeHUh?=
NBsusSR NUj0blBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwM{S5N|gh|ryP NXLBd5k1W0GQR1XS
AN3-CA MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNwNESyN|gh|ryP MXHTRW5ITVJ?
EFM-19 M4DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD1|LkS4N|M6KM7:TR?= NXizdXVYW0GQR1XS
RVH-421 NWDPNZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDG[ZpSUUN3ME2zMlU3QDd5IN88US=> MlfvV2FPT0WU
5637 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2xbFdKSzVyPUOuOlEyODNizszN NEHI[ItUSU6JRWK=
PANC-08-13 NGHH[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLZXoc6UUN3ME2zMlY{PDd{IN88US=> M1zDd3NCVkeHUh?=
H9 NVTsSVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi0TGhKSzVyPUOuOlcyPDRizszN MlHMV2FPT0WU
KARPAS-299 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwNkezOlEh|ryP NXfOPGZRW0GQR1XS
TE-5 M3u0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNwN{C3NFkh|ryP NHHKd3FUSU6JRWK=
NOS-1 M17MVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XQemlEPTB;Mz63PVg{PCEQvF2= MXLTRW5ITVJ?
HH NXOzcpU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LqTWlEPTB;Mz64N|g3QCEQvF2= MoXKV2FPT0WU
769-P M1zzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfrdlZKSzVyPUOuPFk2OSEQvF2= NGHJe2RUSU6JRWK=
CHP-212 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwOUK1OFkh|ryP MofwV2FPT0WU
NCI-H82 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNwOUW5N|Yh|ryP MkLBV2FPT0WU
Mo-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRwMESzNVIh|ryP M1LIPHNCVkeHUh?=
BB65-RCC NID0dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HZPGlEPTB;ND6wOFM6QSEQvF2= M4[0TnNCVkeHUh?=
SW1990 NH\YXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\tXJRKSzVyPUSuNFU6ODhizszN MVzTRW5ITVJ?
LK-2 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jsUmlEPTB;ND6xNVI6OyEQvF2= NVvYeppxW0GQR1XS
ES5 NXTROGJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PLXmlEPTB;ND6xN|k5PSEQvF2= MVTTRW5ITVJ?
JVM-3 NYLYXHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xw[2lEPTB;ND6xPFIzOiEQvF2= NXfP[VcyW0GQR1XS
RPMI-7951 NH7Rd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPBTZcxUUN3ME20MlIzPDF|IN88US=> NVvDTJdVW0GQR1XS
Calu-6 NGrkeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvleoxKSzVyPUSuNlc5QDFizszN NX;MT4ViW0GQR1XS
LC-2-ad NFLWbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17jZWlEPTB;ND6yPVU3QCEQvF2= MVfTRW5ITVJ?
SW954 NGnHb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwMkm2OkDPxE1? NGTNbFZUSU6JRWK=
H-EMC-SS NE\rcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCyTWM2OD12LkOxPFMyKM7:TR?= MXXTRW5ITVJ?
ES3 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\vdYxKUUN3ME20MlM2PDRzIN88US=> M1fET3NCVkeHUh?=
no-11 NUDvTHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXwRoVyUUN3ME20MlM2PTV2IN88US=> MYHTRW5ITVJ?
LAN-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DqTWlEPTB;ND60OVE5QSEQvF2= NGGyRoZUSU6JRWK=
FTC-133 NETsUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQOo1HUUN3ME20MlU{QTVizszN MVnTRW5ITVJ?
8505C MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnjWZJKSzVyPUSuOVQzOyEQvF2= M3;5THNCVkeHUh?=
SW620 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\Fc4FKSzVyPUSuOVcxPTdizszN NUTBWphFW0GQR1XS
BCPAP NIDOeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33iVWlEPTB;ND62N|Q5OSEQvF2= M32xeHNCVkeHUh?=
SK-LU-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwNk[wPFkh|ryP NWr0Z5pCW0GQR1XS
NCI-H1623 M{fmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO4ZopKSzVyPUSuO|AzOjhizszN NWjCbXVwW0GQR1XS
C2BBe1 NYXPWVM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkniTWM2OD12Lke0NFA5KM7:TR?= M3TD[nNCVkeHUh?=
GP5d M{LmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7HZmZYUUN3ME20Mlc5Ozh6IN88US=> MXHTRW5ITVJ?
NB6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwOE[yNFQh|ryP NFKzU4ZUSU6JRWK=
MDA-MB-157 NHroPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLOTWM2OD12Lki4O|Yh|ryP Mlq2V2FPT0WU
UMC-11 M1TN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnmVpF3UUN3ME20Mlg5QTZ2IN88US=> MoPNV2FPT0WU
HCC1419 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnUZmpNUUN3ME20MlkxODZ|IN88US=> M2nPb3NCVkeHUh?=
NCI-H2029 M2T1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTRwOUSxPFUh|ryP NWXwOmJ5W0GQR1XS
LXF-289 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVwMEO3NVkh|ryP MoLVV2FPT0WU
KINGS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzvTWM2OD13LkC3O|Q1KM7:TR?= Mm\ZV2FPT0WU
HD-MY-Z NY[x[2hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXsV5dKSzVyPUWuNlM6PjlizszN MVzTRW5ITVJ?
ESS-1 NXTRfpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCyTWM2OD13LkK1OVk4KM7:TR?= MmHNV2FPT0WU
GI-1 NUK1U4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OxcmlEPTB;NT6yO|kzPiEQvF2= MnHoV2FPT0WU
RPMI-2650 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH4W5lKSzVyPUWuN|YyPiEQvF2= NVe5dJRjW0GQR1XS
IA-LM NGnaZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;Db45KSzVyPUWuN|k5PzFizszN NVm5coRoW0GQR1XS
KP-4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;mT2JtUUN3ME21MlQ3OzN2IN88US=> NWWzbIhYW0GQR1XS
G-402 NIS1XllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHFUGFKSzVyPUWuOVE5PjVizszN NXm5fJJ[W0GQR1XS
OS-RC-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7oPXdKSzVyPUWuOVI3ODRizszN M2rWOXNCVkeHUh?=
NCI-H1155 NFLuPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfJ[VBbUUN3ME21MlU1QTV3IN88US=> NUL4T|ZEW0GQR1XS
OE19 MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi1SHRKSzVyPUWuOlg3OjRizszN M3ewN3NCVkeHUh?=
U-2-OS MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMV2R4UUN3ME21Mlg6ODF|IN88US=> Mn;HV2FPT0WU
SCC-15 NETaSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj6TWM2OD13LkmzOlYzKM7:TR?= NInw[ZFUSU6JRWK=
NCI-H630 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHVbWtPUUN3ME21Mlk6PDB2IN88US=> NGn6O4tUSU6JRWK=
PFSK-1 NGe0SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki3TWM2OD14LkC1NlU6KM7:TR?= MlzKV2FPT0WU
NCI-H1770 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DLVGlEPTB;Nj6yNFg4PCEQvF2= MWHTRW5ITVJ?
SK-MEL-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDRZWxKSzVyPU[uOFI6OTVizszN MWnTRW5ITVJ?
LB1047-RCC NU[5ZWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmbmlEPTB;Nj60O|YzPSEQvF2= M{P3TnNCVkeHUh?=
NCI-H446 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4[2lEPTB;Nj62NlkzPSEQvF2= Mn2zV2FPT0WU
SW780 M124bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;5eGlEPTB;Nj63NFE5PSEQvF2= M1TncHNCVkeHUh?=
NEC8 NX\Ee5V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTGdoVNUUN3ME22Mlc3PjNizszN NXezOlFFW0GQR1XS
NOMO-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELFbXVKSzVyPU[uO|gyOTFizszN NVzweGlPW0GQR1XS
COLO-668 NEfaT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PYXGlEPTB;Nj64OFM5PyEQvF2= MV;TRW5ITVJ?
MC116 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwOUO4PVch|ryP MX7TRW5ITVJ?
HCC1937 NFXJOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;QTWM2OD14Lkm5NlUyKM7:TR?= M37pdnNCVkeHUh?=
NCI-N87 M1O4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPl[XFTUUN3ME23MlE6Ojl|IN88US=> M4Dkd3NCVkeHUh?=
COLO-320-HSR M3q3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdwMkK3N|gh|ryP NIPWZnZUSU6JRWK=
HCC1806 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTJeZFKSzVyPUeuNlYxPDRizszN Mn;3V2FPT0WU
OVCAR-3 NYD4[5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fzeWlEPTB;Nz6zN|A{QCEQvF2= NGfuUmNUSU6JRWK=
NUGC-3 NEnDWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLZTWM2OD15LkO5Olk1KM7:TR?= NV7rOJc{W0GQR1XS
SW1783 NVjmd|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXexbFZ[UUN3ME23MlQ{OTd3IN88US=> NIruNlVUSU6JRWK=
GCT MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFflfoxKSzVyPUeuOVY6ODZizszN M4fndXNCVkeHUh?=
NCI-H2126 M2TrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILT[3dKSzVyPUeuO|M3OjVizszN NGDv[2ZUSU6JRWK=
MEL-HO M2rsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWraenVrUUN3ME23Mlc4ODV2IN88US=> Mo\vV2FPT0WU
CAPAN-1 NWHZZZU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz1XoRbUUN3ME23Mlc4OzV5IN88US=> M4WybnNCVkeHUh?=
SW756 NHjifYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTdwN{izN|Mh|ryP MYXTRW5ITVJ?
SKG-IIIa MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS5fpJGUUN3ME23MlgyQDl{IN88US=> NXvN[nZmW0GQR1XS
HCE-T MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPkXYRoUUN3ME23Mlg4Pzh|IN88US=> NV6wUlBKW0GQR1XS
Ca-Ski NYGwdXpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\uTWM2OD15Lkm5N|g{KM7:TR?= NETuRldUSU6JRWK=
COLO-684 NGXVZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3STWM2OD16LkCxPFE5KM7:TR?= Mn3SV2FPT0WU
KYSE-70 NGnEPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W3c2lEPTB;OD6wO|czQSEQvF2= NGXsS2hUSU6JRWK=
TI-73 NV7FZZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2UXBKSzVyPUiuNlU5PTFizszN NEOyfnZUSU6JRWK=
BT-20 NXrQNGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPNTWM2OD16LkK2NFUzKM7:TR?= NELCbVdUSU6JRWK=
MHH-ES-1 NHHHSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ke|ZKSzVyPUiuOVE5OzRizszN NGL6WGtUSU6JRWK=
TE-12 NIiyTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\x[GlEPTB;OD61PVk{OSEQvF2= M2fndXNCVkeHUh?=
YH-13 NH70NnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRThwNkGwNFgh|ryP MV7TRW5ITVJ?
SF126 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O0eGlEPTB;OD64N|g3PSEQvF2= M2nIOXNCVkeHUh?=
J82 NGPOdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojiTWM2OD16LkmwNFM5KM7:TR?= MVLTRW5ITVJ?
RCC10RGB NGPCfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRThwOUm1OlEh|ryP MX;TRW5ITVJ?
SK-UT-1 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2POc2lEPTB;OT6wOFk1PSEQvF2= NE\GcmtUSU6JRWK=
LB2241-RCC M4\GPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXMTWM2OD17LkG5NVM4KM7:TR?= MWfTRW5ITVJ?
LB996-RCC MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX32W411UUN3ME25MlE6QDlizszN MmjaV2FPT0WU
EPLC-272H M4jIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7LTWM2OD17LkO3OlU4KM7:TR?= NF3kNIFUSU6JRWK=
CTV-1 NGPRUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;MWmVXUUN3ME25MlU3PTN{IN88US=> NX3YUWxbW0GQR1XS
HSC-2 NHfiN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTlwNUe1OUDPxE1? M2XlN3NCVkeHUh?=
SK-MEL-28 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTlwNkG4PVMh|ryP MVjTRW5ITVJ?
MMAC-SF NWn3[GhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTlwNki3OUDPxE1? M3XkcnNCVkeHUh?=
CP50-MEL-B NWjKXVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WycWlEPTB;OT63OVc5OiEQvF2= MoXzV2FPT0WU
HT-1080 M1\XRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P2R2lEPTB;OT63O|c{QSEQvF2= MWjTRW5ITVJ?
HEC-1 NWr1TnpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zXb2lEPTB;MUCuN|M2OiEQvF2= MmH1V2FPT0WU
AGS MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrLTWM2OD1zMD6zO|Qh|ryP MlvVV2FPT0WU
GAMG MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TxWmlEPTB;MUCuOVE3OiEQvF2= MmHqV2FPT0WU
SW48 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\BfFZ{UUN3ME2xNE42OTh7IN88US=> MVfTRW5ITVJ?
U031 NFHnVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33LUGlEPTB;MUCuOVkxQCEQvF2= NHPaZ2FUSU6JRWK=
OVCAR-5 NYrXVpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjuWpV4UUN3ME2xNE43PDJ7IN88US=> MonqV2FPT0WU
SF295 NGC5TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm2VHZnUUN3ME2xNE43PzB2IN88US=> MYLTRW5ITVJ?
BHT-101 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfhW2xSUUN3ME2xNE44OTd5IN88US=> MY\TRW5ITVJ?
VMRC-RCZ M3jBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXoTWM2OD1zMT6zNlAyKM7:TR?= NXPn[XlWW0GQR1XS
ACHN NFv4ZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofWTWM2OD1zMT60NlEyKM7:TR?= NF\HblFUSU6JRWK=
NCI-H526 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf1Zmc2UUN3ME2xNU42ODR|IN88US=> MmjGV2FPT0WU
MN-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7Wc|BKSzVyPUGxMlU{QSEQvF2= NWLYbYhrW0GQR1XS
NCI-H2291 NHHQe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fVdGlEPTB;MUGuOVQ3PiEQvF2= M2O5SHNCVkeHUh?=
SCC-25 M1Xy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f3ZWlEPTB;MUGuO|U2PiEQvF2= NVW2OY84W0GQR1XS
SK-MEL-2 M{fQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{POdWlEPTB;MUGuO|Y{PyEQvF2= MVHTRW5ITVJ?
SN12C MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\6V21KSzVyPUGxMlk{PTVizszN M{Xse3NCVkeHUh?=
NCI-H69 M1fKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{LkSyN|Qh|ryP NVf6RZBUW0GQR1XS
ME-180 NUnkVWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HtR2lEPTB;MUKuO|A2PCEQvF2= NXPvbI1lW0GQR1XS
MC-IXC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C0dGlEPTB;MUKuO|UyQCEQvF2= NYC4PIR7W0GQR1XS
NCI-H2347 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULzWVBLUUN3ME2xNk44PjF2IN88US=> M2fhbnNCVkeHUh?=
M059J MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF{Lke3Nlch|ryP NEPqRlRUSU6JRWK=
A2058 NUXEc4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu5OZlKSzVyPUGyMlg3QDFizszN M{\LUnNCVkeHUh?=
VA-ES-BJ NVrl[IxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\I[Gh3UUN3ME2xNk45Pzh3IN88US=> NWHNOpBbW0GQR1XS
Ca9-22 M1vHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nYTmlEPTB;MUKuPVQ2OSEQvF2= M2flXHNCVkeHUh?=
KNS-42 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTM[25KSzVyPUGyMlk6QDRizszN Mnm1V2FPT0WU
LoVo MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyS2lEPTB;MUOuNlMyOyEQvF2= M4\6e3NCVkeHUh?=
AM-38 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW0bm9rUUN3ME2xN{4zPTZ4IN88US=> M3zPeXNCVkeHUh?=
NB5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jhOWlEPTB;MUOuN|c2OiEQvF2= Mm\oV2FPT0WU
L-363 M1;qW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\tTWM2OD1zMz60NFM{KM7:TR?= M3nyUnNCVkeHUh?=
SK-MEL-30 NGCzU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF2LkC2OFUh|ryP NWLrNXJ2W0GQR1XS
NCI-H1563 NIS5SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfRWIRSUUN3ME2xOE43ODN7IN88US=> M4jzXHNCVkeHUh?=
NCI-H2228 M4LteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[yOmlEPTB;MUSuOlA4PyEQvF2= MmPYV2FPT0WU
MFM-223 NI[zbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvuTWM2OD1zNT6xPFE{KM7:TR?= M{HWcHNCVkeHUh?=
LB831-BLC M3W3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUdnFFUUN3ME2xOU4zPzZ5IN88US=> NFK2RoVUSU6JRWK=
SW872 NH\YTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfC[3d6UUN3ME2xOU4{ODh4IN88US=> MlvOV2FPT0WU
NCI-H522 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPnTWM2OD1zNT6zN|A3KM7:TR?= M4n2NHNCVkeHUh?=
EW-1 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmSnlNUUN3ME2xOU42PDZ{IN88US=> M3e4V3NCVkeHUh?=
HN NYjJNlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof0TWM2OD1zNT61PVQzKM7:TR?= NWXjd4w4W0GQR1XS
SW837 NYKwNVRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3izSGlEPTB;MUWuO|g1PyEQvF2= MUHTRW5ITVJ?
SCC-9 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jvWWlEPTB;MUWuPFEyPCEQvF2= NXX2c4NLW0GQR1XS
MKN7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF3Lkm3N|Ih|ryP NXX5bWQ3W0GQR1XS
KYSE-410 NUnpenVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW3TWM2OD1zNj61PVEh|ryP M3PVOXNCVkeHUh?=
SK-N-DZ MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF4Lk[xNVYh|ryP MX\TRW5ITVJ?
COR-L105 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PuV2lEPTB;MU[uOlUzQCEQvF2= NW[yUIE5W0GQR1XS
LB2518-MEL NG[zTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF4LkizPFkh|ryP NVqwXnc4W0GQR1XS
OVCAR-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPkTJhKSzVyPUG2Mlg5PjJizszN M{TRWnNCVkeHUh?=
TK10 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r5XmlEPTB;MU[uPVQ4OyEQvF2= NXfiUmFCW0GQR1XS
KNS-62 M{XBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF4Lkm3O|ch|ryP MVvTRW5ITVJ?
RPMI-8866 M4DKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\vfGxKSzVyPUG3MlE4OzJizszN M3zwU3NCVkeHUh?=
HuP-T4 NVr1VnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KwXWlEPTB;MUeuNlQ6PSEQvF2= MmrSV2FPT0WU
CGTH-W-1 NIfVdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;OVVVKSzVyPUG3MlUzOTlizszN NIX5NmlUSU6JRWK=
T-24 M{XyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TNS2lEPTB;MUeuOVM1PyEQvF2= MnzMV2FPT0WU
HT-3 NUPZZYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLLUJdQUUN3ME2xO{42QTF2IN88US=> MV\TRW5ITVJ?
KS-1 NGjzTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rwfWlEPTB;MUeuOlc{KM7:TR?= M{TVWXNCVkeHUh?=
NCI-H1792 M{TET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTBSm1KSzVyPUG3Mlc6QCEQvF2= M2nTVXNCVkeHUh?=
ABC-1 NYLSdm02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW3TWM2OD1zNz64NVQyKM7:TR?= MV3TRW5ITVJ?
BPH-1 NVfPPYNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnMTWM2OD1zOD6xOlg2KM7:TR?= NH7m[XRUSU6JRWK=
A431 NHn5e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTsbpVNUUN3ME2xPE41OTJ5IN88US=> M3qwTnNCVkeHUh?=
T98G NFfO[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS3c2N3UUN3ME2xPE42OTV5IN88US=> MmXsV2FPT0WU
BHY MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnFTWM2OD1zOD64Olkh|ryP NFLiV5hUSU6JRWK=
Capan-2 M4jSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXuTWM2OD1zOD65NFc5KM7:TR?= MXfTRW5ITVJ?
MDA-MB-175-VII M1POZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vibGlEPTB;MUiuPVIxQSEQvF2= MoqyV2FPT0WU
CAL-27 NGqxWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfyTWM2OD1zOT6wOFg4KM7:TR?= MlnRV2FPT0WU
AsPC-1 NG\6SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\mW5JlUUN3ME2xPU45PjV5IN88US=> MmDwV2FPT0WU
KU812 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF7Lkm1O|Mh|ryP MUTTRW5ITVJ?
NCI-H441 M1HqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHGOIRKSzVyPUKwMlAxOSEQvF2= MnjjV2FPT0WU
Mewo NIfoT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofZTWM2OD1{MD6xNlg5KM7:TR?= NWTxR|F5W0GQR1XS
SK-MEL-24 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJyLkG0O|ch|ryP NXfDbIV6W0GQR1XS
NCI-H727 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTpWpA4UUN3ME2yNE4zPzB2IN88US=> NFzVOJNUSU6JRWK=
EKVX M37sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXXbnVZUUN3ME2yNE43ODZizszN MWfTRW5ITVJ?
RT-112 NIjQNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PRTmlEPTB;MkCuOlEzOiEQvF2= NITJcJRUSU6JRWK=
CAMA-1 NVTweHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3VRVBmUUN3ME2yNE46QDB|IN88US=> MlLGV2FPT0WU
SW900 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[3UpFKSzVyPUKxMlAyPDlizszN NXPMTmpJW0GQR1XS
NCI-H23 NVThfpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJzLkGyO|ch|ryP NFO3SHBUSU6JRWK=
SK-PN-DW NXTqcox3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnlbVZKSzVyPUKxMlE3PDlizszN NYHrdHpTW0GQR1XS
BB30-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\VTWM2OD1{MT6yO|Q2KM7:TR?= M3PtfXNCVkeHUh?=
VM-CUB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\pcWlEPTB;MkGuN|U{PiEQvF2= NFfXU2FUSU6JRWK=
IST-MEL1 NH3rc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTPepZKSzVyPUKxMlM3QTJizszN MofoV2FPT0WU
CTB-1 NWXqVZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFniTVFKSzVyPUKxMlQ4PTVizszN MVPTRW5ITVJ?
LCLC-103H MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTjS3AxUUN3ME2yNk4yPTh{IN88US=> NXrxN|hTW0GQR1XS
PANC-03-27 M1L0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ{LkWxOlkh|ryP M{Tub3NCVkeHUh?=
HTC-C3 M4DQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SyU2lEPTB;MkKuOVU2PSEQvF2= MmHCV2FPT0WU
TE-8 M3nU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH5clVCUUN3ME2yN{4zPTZ3IN88US=> MYXTRW5ITVJ?
NCI-H292 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUewN|diUUN3ME2yOU4{PTN4IN88US=> M2HWPXNCVkeHUh?=
COLO-680N MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrNRmZKSzVyPUK1MlY{OjlizszN NGrwUHdUSU6JRWK=
KYSE-520 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn1R|NWUUN3ME2yOU43PDRizszN MVHTRW5ITVJ?
NB10 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxTWM2OD1{Nj6zNVE4KM7:TR?= M2fXPHNCVkeHUh?=
NCI-H661 NFHNZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DoTmlEPTB;Mk[uOFcyOyEQvF2= Mk\hV2FPT0WU
GMS-10 NH;IUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vVPWlEPTB;Mk[uPFY{QCEQvF2= M135XnNCVkeHUh?=
NCI-H2122 NH7XZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDnbpZKSzVyPUK2Mlk6QThizszN NWPKVHNFW0GQR1XS
OVCAR-8 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T2OWlEPTB;MkeuNFY{QCEQvF2= Mn;UV2FPT0WU
DJM-1 M2\iXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fM[WlEPTB;MkeuNVQ2PCEQvF2= Ml;nV2FPT0WU
UACC-893 M4jWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ad2lEPTB;MkeuPVg4QCEQvF2= Mn7SV2FPT0WU
C8166 NWK4bFA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ6Lk[5N|gh|ryP M{LUeHNCVkeHUh?=
NCI-H1693 NVnsUZZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G3c2lEPTB;MkiuOlk4PSEQvF2= MUnTRW5ITVJ?
TYK-nu MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzmTIlKSzVyPUOwMlA{PDVizszN NFPaSm1USU6JRWK=
SW1710 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iyUGlEPTB;M{CuNVI3KM7:TR?= NHO0WJFUSU6JRWK=
A375 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\idFRlUUN3ME2zNE4{OjR|IN88US=> Mo[5V2FPT0WU
HMV-II MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPcI9PUUN3ME2zNU4{PTl{IN88US=> NHzHc2xUSU6JRWK=
NCI-H2087 NFja[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\meGc5UUN3ME2zNU43OzV{IN88US=> NXfrdJFrW0GQR1XS
CAL-54 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrHb4xqUUN3ME2zNU44OjRzIN88US=> NWXVfW9iW0GQR1XS
HCC70 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfSVW9KUUN3ME2zNk4yOzh5IN88US=> MUfTRW5ITVJ?
ES1 NXiyb4xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDmTWM2OD1|Mj6zNFYzKM7:TR?= NFi1VZhUSU6JRWK=
NCI-H1355 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzhTWM2OD1|Mz6yNFQh|ryP NE\P[5pUSU6JRWK=
CFPAC-1 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOzVI93UUN3ME2zN{4zOzN{IN88US=> M17XcXNCVkeHUh?=
MKN28 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HpVmlEPTB;M{OuN|gxQSEQvF2= MW\TRW5ITVJ?
HDLM-2 NWfhZ4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN|Lk[5N|Eh|ryP M4PsWXNCVkeHUh?=
PANC-10-05 NIiwWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTGTWM2OD1|ND6xNFE1KM7:TR?= MXnTRW5ITVJ?
SAS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN2LkS1OlUh|ryP NYPVdZd5W0GQR1XS
HCC1395 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG5TWM2OD1|ND63NVg3KM7:TR?= MmLHV2FPT0WU
8305C NVfIfVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTuUpFRUUN3ME2zOU45PDF3IN88US=> NWm3dpM6W0GQR1XS
KM12 NYTjSFA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN4Lke1OFch|ryP NI\Mbm5USU6JRWK=
SW1116 M{XQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P3PWlEPTB;M{euOVk6OiEQvF2= MYnTRW5ITVJ?
SK-MEL-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yzdWlEPTB;M{iuN|M5QSEQvF2= NFjpPZBUSU6JRWK=
HCC2218 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnVTWM2OD1|OD62OVE6KM7:TR?= NHP6WJRUSU6JRWK=
T84 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofrTWM2OD1|OD63OFA6KM7:TR?= Mmn6V2FPT0WU
ETK-1 NXrkVYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDKXIpKSzVyPUO5MlAzOiEQvF2= NH:2R2RUSU6JRWK=
COLO-800 NFT1WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mxbWlEPTB;M{muN|g3QCEQvF2= M4XZbHNCVkeHUh?=
CAL-12T M3X6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDmelg1UUN3ME2zPU42OjhzIN88US=> M1vSXnNCVkeHUh?=
ACN M{HHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTyTWM2OD12MD60PVEyKM7:TR?= M4LrfXNCVkeHUh?=
SJSA-1 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRzLkG1PVYh|ryP Ml;zV2FPT0WU
PSN1 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK3NlZKSzVyPUSxMlE4PDlizszN NXTU[mkxW0GQR1XS
D-566MG MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3myO2lEPTB;NEGuNlA5PiEQvF2= MVPTRW5ITVJ?
EGI-1 NX;4cVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR{LkSyPEDPxE1? M1u5RXNCVkeHUh?=
A204 M1npNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ZbFFmUUN3ME20Nk43Ozh6IN88US=> MlftV2FPT0WU
Saos-2 M2TjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq4TWM2OD12Mj64N|Y6KM7:TR?= M2nsRnNCVkeHUh?=
SNU-C2B MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknBTWM2OD12Mz62PFc5KM7:TR?= NV:1[lU5W0GQR1XS
HLE MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDLTWM2OD12ND6wPFU3KM7:TR?= MWDTRW5ITVJ?
SW1463 M{fU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTR2Lkm5O|Eh|ryP NXTPSZBHW0GQR1XS
DSH1 NIXG[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5eoxiUUN3ME20OU4xODN|IN88US=> MlXHV2FPT0WU
MCF7 M3TsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17VSmlEPTB;NEWuOVA2OSEQvF2= NH35PZpUSU6JRWK=
K5 NVXpUFFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXvcFRKSzVyPUS1Mlk1ODVizszN M2\JW3NCVkeHUh?=
NCI-H358 M1fxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTR5LkKxOUDPxE1? MlKyV2FPT0WU
NCI-H2030 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTZXYhJUUN3ME20O{4zOzd2IN88US=> MUTTRW5ITVJ?
SW948 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;lOpdKSzVyPUS3MlQ3PCEQvF2= NV35dmhzW0GQR1XS
BALL-1 M4fFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvJRYhKSzVyPUS3MlYyPjhizszN NYPWcppOW0GQR1XS
TE-9 NUXRXYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP0eYhKSzVyPUS3Mlk2QDFizszN M1ThRXNCVkeHUh?=
SK-N-FI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR6LkCzOVgh|ryP NVX5NW83W0GQR1XS
KALS-1 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZTWM2OD12OD6xNlg6KM7:TR?= MV\TRW5ITVJ?
HO-1-N-1 NFzrVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjUeINGUUN3ME20PE44PDR3IN88US=> M1vnTHNCVkeHUh?=
NCI-H2452 NXLV[HI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnhPY1KSzVyPUS5MlEyPTJizszN MlG5V2FPT0WU
OC-314 NEfyVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWxfFhMUUN3ME20PU43QDN2IN88US=> MWLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+corn oil 7mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID